About Whitecap Biosciences
Whitecap Biosciences is a Healthcare company based in United States founded in 2015, and was acquired by Bausch & Lomb in January 2025. It operates as a therapeutics for ophthalmological disorders, including glaucoma treatments, are developed. Its focus areas include Life Sciences, Ophthalmology, Drugs and Diversified.
Company details
Whitecap Biosciences was founded in 2015 in the United States. Focus is placed on the biotechnology sector, where therapeutics for ophthalmological conditions are developed. Operations center on compounds such as WB007, an alpha-2 adrenergic agonist used to enhance vision in glaucoma patients, and WB006, targeted at geographic atrophy. Research and development activities are conducted to address these eye-related disorders.
- Headquarters United States
- SectorsHealthcare
- Acquired by Bausch & Lomb (Jan 2025)
- Investors
- Acquired byBausch & Lomb
(Jan 2025)
Investors in Whitecap Biosciences
Whitecap Biosciences has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Bausch & Lomb.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Ophthalmic pharmaceuticals and instruments are developed for eye care. | 1853 | bausch.com | Bridgewater, United States |
Investor details for Whitecap Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Whitecap Biosciences
2 dated milestones of Whitecap Biosciences across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Whitecap Biosciences is founded.
- Exit Acquired by Bausch & Lomb.
Top companies in Ophthalmology
10 companies that operate in the same segment as Whitecap Biosciences (Ophthalmology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 | |
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. | 2003 | Alpharetta, Georgia, United States | USD 66.8 M | USD 80.75 M | 79 | |
AI-powered portable solutions for ophthalmic screening and diagnosis are developed. | 2009 | Bengaluru, Karnataka, India | USD 25.01 M | USD 4.85 M | 135 | |
Gene therapies for ocular and neurodegenerative diseases are developed. | 2015 | New York, New York, United States | – | USD 81.39 M | 381 | |
Small molecule therapeutics for ophthalmic disorders are developed. | 1987 | Watertown, United States | – | USD 31.37 M | 165 | |
Therapies for metabolic and orphan diseases are developed by Rezolute. | 2012 | Denver, Colorado, United States | – | – | 59 | |
Manufacturer of portable digital eye imaging devices and cloud-based healthcare platforms | 2010 | Bengaluru, Karnataka, India | USD 18.12 M | USD 4.78 M | 145 | |
Therapeutics for retinal diseases are developed by the company. | 2009 | Palo Alto, California, United States | USD 35.84 M | – | 109 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Whitecap Biosciences
Whitecap Biosciences was founded in 2015.
Whitecap Biosciences is headquartered in United States.
Whitecap Biosciences was founded in 2015 in the United States. Focus is placed on the biotechnology sector, where therapeutics for ophthalmological conditions are developed. Operations center on compounds such as WB007, an alpha-2 adrenergic agonist used to enhance vision in glaucoma patients, and WB006, targeted at geographic atrophy. Research and development activities are conducted to address these eye-related disorders.
Whitecap Biosciences has 1 investor. Key investors include Bausch & Lomb.
Yes. Whitecap Biosciences was acquired by Bausch & Lomb in January 2025.